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The primary function of recombinant activated factor VII (rFVIIa) is to increase thrombin formation which leads to increased
ﬁbrin and less “bleeding.” As a result, most of literature utilizes “bleeding” as the outcome measure with respect to rFVIIa.
However, we report the actual eﬀect of rFVIIa on changes in hemostatic markers such as prothrombin activation peptide F1.2,
thrombin antithrombin complex (TAT), D-dimer, tissue plasminogen activator (tPA), and plasminogen activator inhibitor (PAI)
in a neonate after cardiopulmonary bypass. A single dose of rFVIIa caused a 5.5-fold increase in F1.2, 3.5-fold increase in TAT,
and a small increase in d-dimer compared to only a 1.5-fold increase, no increase, and a decrease, respectively, in two neonates
undergoing the same procedure having not received rFVIIa. The patterns of change for tPA and PAI were similar.
Copyright © 2009 Michael J. Eisses et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Recombinant activated factor VII (rFVIIa) is approved for
use to treat bleeding due to hemophilia, especially patients
with known inhibitors to typical factor replacement therapy
[1]. Despite its approved use, rFVIIa has gained attention
for its “oﬀ-label” uses which include treatment of bleeding
due to trauma or surgery, reversal of warfarin therapy,
and treatment of coagulopathies due to liver failure [2].
With regards to trauma and surgery, the medical literature
reporting its “oﬀ-label use” includes mostly case reports
or retrospective reviews with the predominant endpoint
or outcome measure, consisting of a change in bleeding
amounts or blood product administration. With regards
to coagulopathies and warfarin reversal, outcome measures
often include prothrombin time, which is heavily inﬂuenced
by factor VII levels. Other parameters such as partial
thromboplastin time and thrombin time have been included.
However, the main purpose of rFVIIa administration in
surgery or trauma is to increase thrombin formation which
then catalyzes the conversion of ﬁbrinogen to ﬁbrin to make
clot. In searching PubMed, we found no reports of rFVIIa on
hemostatic markers such as F1.2 or TAT. In this case report,
we present the direct changes in several hemostatic markers
(F1.2, TAT, D-dimer, active tPA, and active PAI) due to the
administrationofrFVIIainaneonateduringcardiacsurgery.
2. Case Presentation
A 2-week-old 2.5 kilogram neonate carrying the diagnosis
of d-transposition of the great arteries underwent an arterial
switch procedure using cardiopulmonary bypass (CPB). The
patient had been consented to participate in an investi-
gational review board approved research study involving
the collection of hemostatic markers evaluating the changes
in coagulation and ﬁbrinolysis during CPB. The methods
of that study have been published elsewhere [3]; however,
none of the patients in this case report were included
in previous publications. In brief, blood samples were
collected at various time points during and after surgery,
and levels of the following markers were obtained at each2 Case Reports in Medicine
Table 1:ChangesinMarkerlevelsfrombeforeandafterrFVIIa.nM:nanomolar.pM:picomolar.F1.2:prothrombinactivationfragment.tat:
thrombin antithrombin complex. dd: d-dimer. apai: active plasminogen activator inhibitor type 1. atpa: active tissue plasmingoen activator.
TP8: Time point 8, after protamine or baseline for this report. TP9: Time point 9, 1 hour after surgery or after rFVIIa, if applicable.
Patient receiving rFVIIa? F1.2 (nM) TAT (pM) DD (pM) apai (pM) atpa (pM)
TP8 baseline TP9 TP8 baseline TP9 TP8 baseline TP9 TP8 baseline TP9 TP8 baseline TP9
No 3.8 6.9 505 514 4419 3222 218.7 1524.5 73.4 1.3
No 2 3 356 342 7371 5401 4.5 1013.3 120.8 2
Yes 5 27 536 1927 2364 3081 80.4 453.1 105.8 4.2
time point: prothrombin activation peptide F1.2, thrombin
antithrombin complex (TAT), D-dimer (DD), active tissue
plasminogen activator (active tPA), and active plasminogen
activatorinhibitortype1(activePAI-1).Afterthepatienthad
separated from CPB and had received protamine to reverse
the eﬀects of heparin, a blood sample was obtained as part
of the research protocol. One hour after that sample was
obtained,thispatientreceivedadoseofrFVIIa(90mcg/kgor
225mcg) for continued bleeding despite platelet and plasma
transfusions. Surgery was concluded successfully, and as part
oftheprotocol,anotherbloodsamplewasobtainedonehour
after the end of surgery in the pediatric intensive care unit
(PICU). The same marker levels were evaluated. Using the
blood sample after protamine administration as a baseline,
the sample obtained in the PICU then demonstrated the
eﬀects of the rFVIIa administration. We also include in this
report results from two other patients in the same study with
the same age, diagnosis, and procedure who did not receive
rFVIIa as a comparison. All patients did receive a one time
dose of aprotinin in the CPB pump prime, but none received
any infusion or subsequent doses. The timing of the blood
samples was the same in all three patients.
The patient receiving rFVIIa showed a substantial
increase in both markers of thrombin generation: F1.2 and
TAT. While the two patients not receiving rFVIIa showed
increases of around 1.5 to 1.8 times baseline, the patient
receiving rFVIIa showed an almost 5.5-fold increase in F1.2.
For TAT, the two non-rFVIIa patients showed little to no
change while the patient receiving rFVIIa showed a 3.5-fold
change. The pattern of D-dimer changes was diﬀerent in that
the patient receiving rFVIIa showed a small increase rather
than a decrease as shown in the other two patients. Active
tPA showed similar readings in the 3 patients, and active
PAI-1showedasmallerincreaseintherFVIIa-treatedpatient
compared to the others. See Table 1 for the complete results.
3. Discussion
Normally, when the endothelium of a blood vessel is
disrupted, the thrombophilic subendothelial layer becomes
exposed. Platelets begin to plug the hole by binding with
vonWillebrand factor leading to activation and then further
aggregation with other platelets through ﬁbrinogen ligands.
Upon this framework, stable clot is achieved through throm-
bin formation which then converts the ﬁbrinogen ligands to
ﬁbrin.FactorXawhichisthecatalystforthrombinformation
can be made through two diﬀerent pathways, one involving
a complex with activated factor VII and tissue factor (TF)
and the other involving a complex with activated factors IX
(FIXa) and VIII (FVIIIa). The amount of thrombin made
from endogenous factor VII complexed with TF is small in
comparison to the amount through complexed FIXa/FVIIIa.
However, when recombinant FVIIa is given, the formation
of thrombin shifts to predominantly the FVIIa/TF complex
pathway, and therefore, factors IX and VIII become less
important. This explains why recombinant FVIIa works in
hemophiliac patients with factor VIII or IX inhibitors.
The important regulatory substance to clot formation is
thrombin. Not only does it serve as the catalyst to convert
ﬁbrinogen to ﬁbrin but it also regulates the stimulation of
factorsXI,IX,andVIIItodriveitsownformation.Thrombin
also further stimulates platelets and impacts activation of
tissueplasminogenactivatorwhichistheinitiationsubstance
of the ﬁbrinolytic system that will control the size of the clot
being made. To measure the degree of this stimulation, many
studiesinliteratureutilizemarkerssuchasprothrombinacti-
vation peptide (F1.2) and thrombin antithrombin complex
(TAT). In the case of F1.2, this peptide is released from the
conversion of prothrombin to thrombin. Once thrombin is
made, it is inhibited by antithrombin III making the TAT
complex. Therefore both of these markers become a measure
of thrombin activation, the former, directly, as thrombin
is made, and the other indirectly through inhibition of
thrombin.
Because of the mechanism of recombinant FVIIa, we felt
it prudent to report its eﬀect on these more focused hemo-
static markers. In this case, the large increase in markers of
thrombin generation (F1.2 and TAT) was striking. Generally,
it has been shown that after protamine administration and
into the ﬁrst moments after completion of cardiac surgery a
procoagulant state may already predominate as represented
by increased F1.2 and TAT [4]. That type of response was
dramatically increased as a result of rFVIIa. In the case of
D-dimer (a breakdown product of ﬁbrin), we previously
reported [3] that its typical response after cardiac surgery
in infants is to drop in the postoperative period. However,
the one infant that received rFVIIa showed an increase in
D-dimer postoperatively. One can speculate that this may
be due to the increased ﬁbrin formation associated with
increased thrombin generation. There was little diﬀerence
in the typical drop in active tPA postsurgery in the patient
receiving rFVIIa. Finally, while active PAI has been shown
to increase dramatically postsurgery, the patient receiving
rFVIIa showed a less dramatic increase. Reasons for this are
unclear.Case Reports in Medicine 3
While most reports on rFVIIa in literature center around
outcome measures such as blood loss, in this case we report
its eﬀect on common outcome markers of coagulation and
ﬁbrinolysis. Ultimately, an understanding of how rFVIIa
aﬀects rates of thrombin and ﬁbrin formation and how it
aﬀectsothersystemssuchasﬁbrinolysisorinﬂammationwill
need further study and perhaps modeling techniques.
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